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Abstract  
 
Ketamine is a common anaesthetic that works through complex neural 
mechanisms, including multiple molecular and circuitry targets. Importantly, it 
promotes analgesia, though it also induces undesirable effects, such as agitation, 
disorientation, hallucinations and nausea. Thus, there is an ongoing search for 
novel ketamine analogues that influence a similar repertoire of brain targets as 
ketamine, whose beneficial effects are potentiated. The present project, utilizing 
rats as an animal model, focused on examining functional properties of the ester-
analogue of ketamine, R5, whose potentially beneficial profile had been 
suggested by preliminary studies. First, brain activation patterns following R5 
compared to ketamine (and another ester-analogue control compound, R1) were 
assessed by employing immunohistochemical detection of an immediate-early 
gene product, c-Fos. R5 produced a somewhat similar pattern of activity as 
ketamine, whereas more profound differences in c-Fos were detected after R1. 
It was particularly striking in areas related to pain and addiction, including the 
anterior insular cortex (AIC) and paraventricular nucleus (PVN). Therefore, in 
the subsequent set of experiments, effects of R5 on pain- and addiction-related 
behavioral parameters were assessed in rats injected with R5 
intracerebroventricularly (ICV) or intraparenchymally. It was found that BaCl 
attenuated ICV R5-induced analgesia. AIC administration of R5 produced 
modest analgesia in the tail-flick test. Finally, PVN R5 reduced naltrexone-
precipitated exercise-induced withdrawal. In sum, R5 shows an analgesic effect 
similar to ketamine, most likely by targeting a similar subset of brain sites, 
which suggests that this particular ester-analogue can be considered as a good 
candidate for conceptualizing future pain management strategies.  
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1. Introduction  
 
Anaesthesia has been operationally defined as (1) immobility in response to 
noxious stimuli, and (2) amnesia. Other clinically relevant effects include 
analgesia, or loss of pain sensation, and hypnosis, or the loss of consciousness; 
but such effects do not uniquely define the anaesthetic state [5]. 
A comprehensive electroencephalographic analysis of anaesthetic-induced loss 
of consciousness was conducted by John and Prichep [6]. Using various 
anaesthetic drugs and techniques, they found that loss of consciousness is a 
fairly abrupt transition (less than 20 ms) involving interruption of γ (gamma) 
synchrony between frontal and posterior cortical regions. Similarly, Imas et 
al.[7] showed that volatile anaesthetics disrupt frontal–posterior cortical γ 
synchrony [8]. Gamma (40 Hz) synchrony is currently the best neural correlate 
of consciousness, and anaesthetics disrupt this synchrony by altering London 
dipole forces within hydrophobic regions of microtubule proteins, that allow 
microtubules to synchronise sensory inputs into a conscious experience. 
How this occurs is becoming better understood. Anatomically, general 
anaesthetics have been shown to bind in, and affect various brain regions 
including the posterior cingulate cortex, orbitofrontal cortex, the right angular 
gyri, and the thalamus [9]. Different effects of anaesthesia may be anatomically 
differentiated. Loss of consciousness appears to be associated with the cerebral 
cortex [7; 10; 11], amnesia (loss of memory) with the limbic system [12-14], 
and immobility and analgesia (loss of movement and pain, respectively) with 
the spinal cord [15-18]. 
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1.1 Mechanism of anaesthetic action 
1.1.1 Site of action 
Anaesthetics were found to bind with high affinity in non-polar, hydrophobic 
pockets in receptors for γ-aminobutyric acid type A (GABA-A), nicotinic 
acetylcholine, and glutamate in the brain, and glycine receptors in the spinal 
cord [2].  
1.1.2 How anaesthetics inhibit consciousness 
At the turn of the 20th century Meyer and Overton showed that potency of 
structurally dissimilar anaesthetic gas molecules correlated precisely over many 
orders of magnitude with one factor, solubility in a non-polar, ‘hydrophobic’ 
medium akin to olive oil [19; 20]. In the 1980s Franks and Lieb showed 
anaesthetics acted in such a medium within proteins, suggesting post-synaptic 
membrane receptors were the site of activity [21]. However network-level 
approaches fail to account for the Meyer Overton correlation, and direct 
anaesthetic effects on synaptic receptors are variable and inconsistent. Without 
synapses or networks, single cell organisms like slime mould and paramecium 
perform clever cognitive activities executed largely by cytoskeletal 
microtubules, which are inhibited by anaesthetic gases.  
In the mid-19th century, the famous French physiologist Claude Bernard 
showed that anaesthetic gases reversibly halt purposeful cytoplasmic streaming 
inside slime mould, amoeboid single cell organisms. Bernard saw purposeful 
cytoplasmic activity as an essential feature of living systems, with anaesthesia 
acting in a common, unitary fashion to prevent it [22]. We now know that 
purposeful cytoplasmic activity in both slime mould and brain neurons depends 
on dynamics of cytoskeletal proteins comprising actin filaments and 
17 
 
microtubules [2]. Indeed slime mould movements allow the single cell creature 
to escape mazes, and ‘solve equations’ [23] by purposeful extension of 
cytoskeletal tendrils. Studies following Bernard later showed anaesthetic effects 
on cytoplasmic streaming were mediated directly in the cytoplasm, rather than 
via cell membrane effects [24; 25], Claude Bernard’s anaesthetic action on 
purposeful streaming therefore occurs directly in the cytoplasm. 
In the 1980’s Franks and Lieb found that anaesthetics act directly within proteins, 
in lipid-like, non-polar ‘hydrophobic pockets’ [21], e.g. composed of aromatic 
amino acid π-electron resonance clouds. 
Rod Eckenhoff’s group surveyed all anaesthetic-binding proteins, measuring 
binding of radio-labelled halothane anaesthetic at clinically relevant 
concentrations in brain neurons from mice and human samples. Using 
chromatography they found halothane binding to 23 membrane proteins and 34 
cytoplasmic proteins. Among the cytoplasmic proteins were cytoskeletal 
proteins including actin, and tubulin, the subunit component of microtubules 
[26]. 
1.1.3 Which proteins mediate anaesthesia? 
Proteomic analysis of genetic expression following exposure to the anaesthetic 
halothane in animals suggests functional effects through protein networks 
involved in “neuronal growth, proliferation, division and communication”, all 
microtubule-dependent functions [26]. 
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Under normal conditions, it was shown [27-30] that London force dipoles in 
intra-protein hydrophobic regions coupled and oscillated coherently (gamma 
synchrony), and this coupling was suggested to be necessary for conscious 
awareness. Anaesthetic gases were suggested to bind in these non-polar, 
hydrophobic regions by their own London force coupling, dispersing 
endogenous dipoles 
necessary for 
consciousness [31]. 
Craddock et al. further 
showed that anaesthetic 
gas molecules bound in 
these same regions, and 
could act there to 
prevent consciousness, 
as shown in Fig. 1. This 
has been acknowledged 
as the ‘quantum 
mobility theory’ of 
anaesthetic action [32]. 
 
Amnesia, or impairment of memory formation, is one pillar of anaesthetic action 
and generally ascribed to altering synaptic plasticity. However synaptic 
membrane proteins which mediate synaptic sensitivity are transient and re-
cycled over hours to days, and yet memories can last lifetimes. Craddock et al. 
[33], and Janke & Kneussel [34] have suggested memory is encoded by post-
translational modifications in microtubules in neuronal dendrites and cell bodies, 
Figure 1. Tubulin, dipoles and anaesthetics. (A) Single tubulin 
dimer showing beta monomer (dark grey), alpha monomer (light 
grey), phenylalanine residues (magenta), tryptophan residues 
(blue), tyrosine residues (green), and persistent predicted volatile 
anaesthetic binding sites (red) with (in yellow) a hypothetical 
hydrophobic ‘quantum’ channel of aromatic rings. (B) Aromatic 
rings (e.g. phenyl and/or indole) within hydrophobic channel 
showing oscillating London force dipoles necessary for quantum 
mobility theory. Below, anaesthetics disperse dipoles, preventing 
consciousness [2]. 
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where microtubules are uniquely configured and stable. Anaesthetic effects on 
microtubules could thus account for amnesia, as well as loss of consciousness 
and prevention of purposeful behaviour, which is consistent with empirical 
observations. 
The Meyer-Overton correlation of anaesthetic solubility in olive oil-like media 
to pharmacologic potency ensues from binding by van der Waals London 
(‘dipole dispersion’) forces [2], which are extremely weak quantum-level 
couplings. In London forces, non-polar (but polarizable) electron clouds 
between nearby atoms and molecules induce transient dipoles in each other, like 
tiny bar magnets, which then attract due to charge-separation by the resultant 
attractive Coulomb forces. Polar deviation from perfect non-polarity accounts 
for variable effects among different anaesthetic molecules [35; 36].  
 
Soluble intravenous anaesthetics like propofol, ketamine, etomidate and 
barbiturates have non-polar groups attached to polar structures. As established 
by Meyer and Overton over a century ago, non-polar London force binding is 
the sine qua non of anaesthesia.  Assuming tubulin (or some other protein) were 
the primary on-target binding site for anaesthetics, what is it that anaesthetics 
do there which prevents consciousness? 
In functioning (non-anaesthetised) proteins, interactions among non-polar 
groups in hydrophobic pockets help determine protein conformation and 
function. The interactions occur by van der Waals (London dipole dispersion) 
forces, weak instantaneous dipole–dipole couplings between pairs of 
complementary electrons in molecular orbitals (‘electron clouds’) of adjacent 
non-polar amino acid side groups. 
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Anaesthetics alter the endogenous van der Waals London forces normally 
occurring in hydrophobic pockets which require electron mobility; electron 
pairs must be relatively free to roam among allowed orbitals. Evidence supports 
the idea that anaesthetics retard electron mobility—the movement of free 
electrons in a corona discharge is inhibited by anaesthetics (Hameroff and Watt, 
1983). By forming their own van der Waals London forces in hydrophobic 
pockets, anaesthetics may retard electron mobility required for protein dynamics, 
quantum states and consciousness (Fig. 1A). We may then understand `non-
anaesthetics' as occupying relevant pockets without altering electron mobility, 
and convulsants as occupying relevant pockets and forming cooperative van der 
Waals interactions which enhance electron mobility and protein dynamics (Fig. 
1B). [37] 
The normal function of anaesthetic-sensitive GABA-A and glycine receptors are 
inhibitory; anaesthetics therefore appear to (1) potentiate the activity of 
inhibitory proteins; and (2) inhibit the activity of excitatory receptors.  
Both inhibitory and excitatory protein receptors act collectively. Supporting this 
notion, normal GABA-A and glycine inhibitory action depends on the integrity 
of cytoskeletal microtubules [38; 39]. 
In recent years, Eckenhoff and colleagues have found anaesthetic action in 
microtubules, cytoskeletal polymers of the protein tubulin that form inside brain 
neurons. ‘Quantum mobility’ in microtubules has been proposed to mediate 
consciousness. Through molecular modelling [2] have shown: (1) olive oil-like 
non-polar, hydrophobic quantum mobility pathways (‘quantum channels’) of 
tryptophan rings in tubulin, (2) binding of anaesthetic gas molecules in these 
channels; and (3) capabilities for π-electron resonant energy transfer. This 
energy transfer is due to exciton hopping among tryptophan aromatic rings in 
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quantum channels, a similar to photosynthesis protein quantum coherence. This 
mode of action describes how anaesthetic molecules can impair π-resonance 
energy transfer and exciton hopping in tubulin quantum channels, and thus 
account for selective action of anaesthetics on consciousness and memory. 
The view of anaesthetic mechanism presented here may be summarized as a 
testable two part ‘unitary quantum hypothesis’: (1) Anaesthetics influence 
quantum states responsible for consciousness (i.e., coherent superposition of 
endogenous van der Waals London forces) in hydrophobic pockets of certain 
brain proteins. (2) Anaesthetics act by preventing stable, resonant quantum 
states in these hydrophobic pockets. 
The Penrose–Hameroff model [40-42] shows that ‘preconscious’ quantum 
coherent superposition/quantum computing originates in neuronal microtubules 
and can be sustained on the order of 25 ms (i.e. coherent 40 Hz) until objective 
reductions (‘conscious events’) occur, as conscious moments occur when the 
quantum wave collapses and integrates all the sensory input into a moment of 
consciousness, accounting for the non-computable property of consciousness 
[37]. In summary, macroscopic quantum effects among neural proteins could 
account for enigmatic features of consciousness and anaesthetic action.  
1.2 Ketamine 
Ketamine is one anaesthetic agent commonly used in hospitals around the world, 
and has been shown to bind to NMDA receptors important for learning & 
memory, having an inhibitory effect. 
Ketamine’s widespread use is largely due to its ability to not suppress the 
respiratory system as strongly as other anaesthetics, making it useful in limited 
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oxygen situations, and is one of the only anaesthetics that produce analgesic, 
hypnotic & amnesic effects. 
While ketamine is an effective anaesthetic and tool for understanding 
consciousness, it is reported to have side-effects of agitation/arousal, nausea, 
and is often associated with disorientation and hallucinations, occurring more 
commonly in women & children. 
The history of ketamine begins in the 1950s at Parke-Davis and Company’s 
laboratories in Detroit, Michigan, USA. At that time, Parke-Davis were 
searching among cyclohexylamines for an ‘ideal’ anaesthetic agent with 
analgesic properties.  
Maddox, a chemist, discovered a process which led to the synthesis of 
phencyclidine or PCP [N-(1-phenyl-cyclohexyl)-piperidine] on 26 March 1956 
[45; 46].  
PCP caused increases in blood pressure, respiratory rate and minute volume, 
with conservation of corneal and laryngeal reflexes. These studies revealed 
genuine narcosis, with a cataleptic state, potent amnesia and analgesia produced 
by PCP anaesthesia [47]. EEG showed no signs of producing hypnotic or sleep-
like states, and produced unacceptable reactions in many test subjects [48]. Chen 
[49] defined catalepsy as a ‘characteristic akinetic state with a loss of orthostatic 
reflexes but without impairment of consciousness, in which the extremities 
appear to be paralysed by motor and sensory failure’[48]. 
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Parke-Davis continued to develop related compounds, one of the agents, 
synthesised in 1962 by Calvin Stevens, produced excellent anaesthesia and was 
short-acting. It was selected for human trials as CI-581 [2-(O-chlorophenyl)-2-
methyl-amino cyclohexanone] [45], and because it was a ketone together with 
an amine, was named ketamine (Fig. 3). Surprisingly, McCarthy et al. [50] 
described it in 1965 as being a compound with cataleptic, analgesic and 
anaesthetic action but without hypnotic properties. 
Ketamine was finally 
characterised as a 
dissociative anaesthetic, 
which was later described as 
the electrophysiological and 
functional dissociation 
between thalamocortical and 
limbic systems, characterized by complete analgesia combined with only 
superficial sleep [51]. 
After being patented by Parke-Davis for human and animal use in 1966, 
ketamine became available by prescription in 1969 in the form of ketamine 
hydrochloride, under the name of Ketalar. It was officially approved for human 
consumption by the United States Food and Drug Administration in 1970 and, 
because of its sympathomimetic properties and its wide margin of safety, was 
administered as a field anaesthetic to soldiers during the Vietnam war [48]. 
Ketamine provided potent analgesia but was less potent and of considerably 
shorter duration of action than PCP, particularly with regard to psychic 
problematic effects. The introduction of ketamine in Britain in late 1969 had 
been described as a ‘disaster’ from which the drug never recovered [52]. In 1970, 
Figure 2. Ketamine (CI-581) structure (Mion, 2017). 
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hallucinations were considered so unpleasant that patient acceptance was much 
lower than with the barbiturates [53]. 
In 1971, Sadove et al. [54] demonstrated that ‘subdissociative’ doses 
(0.44mg/kg) of ketamine possessed analgesic properties with moderate side 
effects. 
1.2.1 Emergence Reactions 
Ketamine [racemic (2-(2-chlorophenyl)-2-(methylamino) cyclohexanone] is a 
dissociative anaesthetic with profound analgesic and sympathomimetic 
properties. It has major advantages over opioids: minimal respiratory depression, 
preservation of protective airway reflexes, no hyperalgesic effects, a reduction 
in analgesic tolerance, and efficacy in opioid-resistant pain [55; 56]. The most 
important adverse effects of ketamine are its psychotomimetic properties, which 
occur at drug concentrations of just 100 ng/mL [57]. Because ketamine has an 
elimination half-life of 2 to 3 hours [56; 58]; patients may experience prolonged 
(20–120 minutes) psychic disturbances after anaesthesia. This limits the clinical 
utility of ketamine in adults [59].  
“Emergence reactions” refer to a constellation of subjective effects encountered 
on emergence from ketamine general anaesthesia [60; 61]. Referred to as 
“psychomimetic”, “hallucinogenic”, or “psychedelic”, they include intense 
alterations in mood, perception, thinking, body awareness and self-control. 
Some patients find these terrifying, whereas others do not [57]. 
Subjects have often described altered physical sensations or body image: 
“Floating, very care-free feelings”, “complete annihilation of idea of self” “The 
experience seems to be a mystical experience, an incomprehensible 
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comprehension of the universe. There seemed to be no past, present or future, 
just existence, life and death at the same time.” [57] 
Emergence delirium or excitement were common and these increased somewhat 
in severity with dosage but the pattern of changes was not clear cut. A small 
(2.5-5.0 mg) dose of diazepam intravenously rapidly controlled these symptoms, 
but larger doses re-induced anaesthesia and caused respiratory depression. 
Except with the smallest induction dose, ketamine was followed by more 
vomiting and/or nausea than methohexitone. The difference was particularly 
marked 1-6 hours after anaesthesia where the incidence with any dose of 
ketamine was significantly higher (P<0.05) than with methohexitone [53]. 
Patient acceptance was lower than any alternative drug, therefore there is still a 
need for analogues with much shorter half-lives to avoid the concomitant use of 
sedatives/ hypnotics [53]. 
Ketamine analogues with very rapid clearance might limit the psychomimetic 
period to only a few minutes [59]. 
 
1.2.2 Modified ketamine: Strategy to improve clinical use of 
ketamine 
In developing a novel analogue to overcome these limitations, the limited 
structure–activity relationships of analogues of ketamine have shown that its 
anaesthetic effects are related closely to its physicochemical properties, with its 
(more polar) secondary 6-hydroxy metabolite having no anaesthetic properties 
[62]. This suggested to Harvey et al., [59] that an ester with similar lipophicity 
to ketamine might retain desirable anaesthetic properties, but would be rapidly 
hydrolysed by serum esterases to the corresponding very polar and thus non-
anaesthetic ionised acid. SN 35210 (R1) was the first ketamine ester-analogue 
26 
 
designed for rapid offset via esterase-mediated hydrolysis. The compounds of 
interest were synthesized from norketamine Fig. 4(1), prepared from 
commercially available (2-chlorophenyl)(cyclopentyl) methanone. 13 Esters 
were then prepared by treatment of norketamine with the appropriate alkyl 
halides Br(CH2)nCO2(CH2)R, and converted to the hydrochloride salts with 
HCl gas (Fig. 4). Purity was determined by high-performance liquid 
chromatography (HPLC) monitoring at 272 nm and was ≥95% for all 
compounds [59]. 
 
 
  
Figure 3. Synthesis of study drugs (R1–R5) from norketamine (1). 
Structure of ketamine provided for comparison. All analogues are 
racemic save R2, which is the S-enantiomer of R1. Me = methyl; Et = 
ethyl; iPr = isopropyl. (Harvey et al., 2015). 
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1.3 Associated brain regions 
Ketamine anaesthesia produces changes in neuronal activity within a variety of 
networks, particularly those associated with nociception, stress and reward 
circuitry, and even addiction-related pathways. By understanding the role each 
of these brain regions play, brain activation may be compared after different 
treatment drugs to help select behavioural studies that can further investigate 
these findings. 
 
1.3.1 Rostral agranular insular cortex: Nociception pathway 
The connectivity of the rostral agranular insular cortex (RAIC) suggests it is 
involved in multiple aspects of pain behaviour (Fig. 5). Projections to the RAIC 
from medial thalamic nuclei are associated with motivational/affective 
components of pain. RAIC projections to mesolimbic/mesocortical ventral 
forebrain circuits are likely to participate in the sensorimotor integration of 
nociceptive processing, while its brainstem projections are most likely to 
contribute to descending pain inhibitory control [63]. 
  
Figure 4. RAIC pain pathways (Jasmin et al., 
2004). 
28 
 
1.3.2 Area postrema: Nausea 
This region is associated with nausea, therefore decreased neuronal activity here 
may imply a reduction in symptoms of nausea (Fig. 6). One study on anaesthesia 
with nitrous oxide found that the euphoric properties of nitrous oxide may be a 
reflection of the neuronal activity of mesocortical dopaminergic projection, 
whereas the increased incidence of post-exposure emesis (nausea) may be a 
reflection of the neuronal activity of the medullary dopaminergic system [64].  
 
 
 
 
 
 
 
1.3.3 Nucleus of the solitary tract: Peripheral sensory relay center 
The nucleus of the solitary tract (NTS) plays a pivotal role in neural cardiovascular 
regulation and integration [65]. Integrating nociceptive and cardiorespiratory 
afferents, the NTS plays a major role in mediating the reflex tachycardia evoked 
by somatic noxious stimulation [66]. 
The nucleus of the solitary tract (NTS) is a key gateway for meal-related signals 
entering the brain from the periphery. One study found that increased activity 
correlated with reduced appetite and body weight [67]. 
Figure 5. Medulla nausea pathway (Murakawa et al., 1994) 
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Satiety signals arising from the gastrointestinal (GI) tract and related digestive 
organs during food ingestion and digestion are conveyed by vagal sensory 
afferents to the hindbrain nucleus of the solitary tract (NTS) [68]. Chronic stress 
causes hypothalamo–pituitary–adrenal (HPA) axis hyperactivity and 
cardiovascular 
dyshomeostasis. 
Noradrenergic (NA) neurons 
in the nucleus of the solitary 
tract are considered to play a 
role in these changes. Studies 
have suggested that 
corticotropin-releasing 
hormone (CRH) originating 
within the hypothalamic 
paraventricular nucleus (PVN) 
acts in the nucleus of the 
solitary tract (NTS) to regulate 
sympathetic and 
cardiovascular functions [69]. 
 
1.3.4 Bed nuclei of the stria terminalis: Anxiety, addiction and 
stress response 
Emerging evidence suggests the bed nucleus of the stria terminalis (BNST) 
mediates both anxiety and addiction through connections with other brain regions, 
including the amygdala and nucleus accumbens [70]. Rodent studies provide 
compelling evidence that the BNST plays a central role in sustained threat 
Figure 6. Characterization of cortical and subcortical 
influence on baroreflex function. Nucleus tractus 
solitarius (NTS), nucleus ambiguus (NA), and dorsal 
motor vagal nucleus (DMV) are important structures 
involved in efferent and afferent vagal activity. The 
lateral hypothalamus (lat HT) and the amygdala 
(basolateral nucleus, BL) generate inhibitory control over 
parasympathetic structures in the brain stem during 
stressful events and in anxiety. In contrast, the medial 
prefrontal cortex (mPFC) and the orbitofrontal cortex 
(OFC) facilitate vagal output and inhibit the rostral 
ventrolateral medulla (RVLM). −, mainly inhibitory 
influence; +, facilitatory influence (Bär et al., 2007). 
30 
 
monitoring, a form of adaptive anxiety, and in the withdrawal and relapse stages 
of addiction [71]. 
The BNST is ideally situated to instigate allostatic changes in the brain through its 
dense connections with the paraventricular nucleus (PVN) of the hypothalamus, 
the node of the hypothalamic–pituitary–adrenal (HPA) axis that initiates cortisol 
responses. Indeed, BNST lesions alter stress-related cortisol release [72], 
suggesting that 
the BNST may 
play an important 
role in disorders 
triggered by stress 
response, 
including 
anxiety and 
addiction (Fig. 
8) [71]. 
 
  
Figure 7. Human anxiety and addiction circuits. The BNST is a central node 
in both anxiety and addiction neurocircuitry. (left) The BNST is centrally 
located to influence human anxiety responses, with connections to 
multiple limbic and brainstem regions that mediate defensive response to 
threat, including the amygdala, anterior insula, hippocampus, 
hypothalamus, and periaqueductal gray. (right) The BNST is engaged 
during the negative emotional stage of withdrawal and interacts with the 
amygdala and ventral striatum, including the shell of the nucleus 
accumbens and ventral tegmental area, to mediate negative 
reinforcement.  
AI, anterior insula; Amyg, amygdala; BNST, bed nucleus of the stria 
terminalis; Hy, hypothalamus; PAG, periaqueductal gray; VS, ventral 
striatum (S. Avery et al., 2016). 
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1.3.5 Amygdala: Emotion and memory 
The amygdala is a heterogeneous structure that has been implicated in a wide 
variety of emotion-related functions, most notably in fear conditioning, and is 
made up of distinct regions including the basolateral amygdala (BLA) and central 
nucleus of the amygdala (CeA). The BLA mediates associations between 
predictive stimuli and the sensory properties of biologically significant events, and 
the CeA mediates the association of predictive stimuli with the affective or 
emotional properties of those events. Whereas the BLA mediates the emotional 
significance of 
specific rewards, the 
CeA seems to 
establish the general 
affective response that 
underlies the 
nonspecific 
reinforcing effect of 
those events [73]. 
 
 
 
1.3.5.1 Basolateral amygdala: Fear response 
The basolateral amygdala has been implicated in unconscious processing of threat-
response [74] and acquisition of conditioning/reward-seeking behaviour [75]. 
Extensive work using pavlovian fear conditioning procedures revealed a role for 
the basolateral amygdala (BLA) in both the acquisition and expression of 
Figure 8. Cannula placement in the BLA. (A) Representative 
photomicrograph illustrating the placement of a cannula and 
needle tip in the BLA. Arrow points to the needle tip. B, basal; AB, 
accessory basal; CEA, central amygdala; La, lateral amygdala. (B) 
Infusion needle tips in the BLA of 30 randomly selected rats 
included in the experiment. (Roozendaal et al., 2006). 
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conditional fear [76]. Lesions of the BLA have been shown to inhibit the 
acquisition of fear response and conditional learning, implicating the integrity of 
this region as important for conditional learning. The suppression of fear 
behaviour by intra-BLA muscimol (inhibition) was associated with increased c-
Fos expression in the central nucleus of the amygdala (CeA) [77]. 
1.3.5.2 Central nucleus of the amygdala: Stimulating emotional 
response 
The CeA has been found to play a role in mediating fear- and anxiety-related 
behavioural and endocrine responses. Ablation studies show it is responsible 
for freezing behaviour upon perceiving a threat, and production of corticotrophin-
releasing factor (CRF), suggesting the CeA is involved in mediating fear- and 
anxiety-related behavioural and pituitary-adrenal responses, as well as in 
modulating brain CRF activity [78]. Similarly, the suppression of fear behaviour 
by intra-BLA muscimol (inhibition) was associated with increased c-Fos 
expression in the central nucleus of the amygdala (CeA) [77]. 
1.3.5.3 Caudate Putamen: Memory-retrieval, habit-formation 
and learned response 
Modulated by the amygdala, this region is important for memory and learning. In 
studies, neuronal activity of the dorsolateral CPU attenuates cocaine-seeking 
behaviour after abstinence and inhibits explicit conditioned-stimuli- and context-
induced reinstatement after extinction training, implicating the CPu in habit 
learning [79].  The dorsolateral caudate putamen (dlCPu), a mediator of stimulus–
response associations [80], exerts more fundamental influence over cocaine 
seeking after abstinence than other brain regions. Dopaminergic neuron activity 
in the dlCPu has been associated with presentation of reward-paired stimuli [81]. 
Stimulation studies show that the caudate putamen is required for the expression 
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and consolidation of memory, while inhibition results in attenuated memory 
consolidation and retrieval 
[82], and has been implicated 
in hallucinations, mediating 
prefrontal behaviours and in 
the conceptual integration of 
memories [83]. 
 
 
 
1.3.6 Paraventricular nucleus of the thalamus: Arousal 
The paraventricular nucleus of the thalamus (PVT) is part of a group of midline, 
and intralaminar thalamic nuclei which are hypothesized to play a role in arousal 
[84-86]. While the function of the PVT remains poorly understood, experiments 
looking at the expression of Fos protein as a measure of neuronal activity have 
consistently shown that neurons in the PVT are activated during periods of arousal 
[86].  The PVT has also been implicated in the regulation of food intake and 
hypothalamic–pituitary–adrenal activity during chronic stress [87]. Based on the 
evidence that the PVT is involved in arousal and receives a substantial orexin 
innervation, it is reasonable to suggest that the PVT may play a part in the arousal 
functions of orexins. 
In turn, the PVT could integrate information from a number of arousal centers and 
relay this information to the nucleus accumbens, amygdala, and prefrontal cortex 
to place these forebrain structures in a state of arousal or readiness necessary for 
behavioural responding. For example, the nucleus accumbens is connected with 
Figure 9. A schematic drawing of the largest and smallest 
lesions of the medial caudate nucleus (medial CPu). The 
lesioned areas are represented by the shaded areas. 
(Packard & Teather, 1998) 
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behavioural motor control systems and has been implicated in defensive 
behaviours and feeding [88]. 
Thus, with afferents from brainstem and hypothalamic cell groups and efferents 
to limbic centers, the PVT is in a position to integrate visceral and circadian 
information, and modulate limbic functions. In addition to HPA activity, chronic 
stress also modifies activity in systems that regulate core temperature and energy 
balance [87]. 
1.3.7 Hypothalamus 
1.3.7.1 Paraventricular nucleus of the hypothalamus: Stimulating 
stress 
response 
The paraventricular 
nucleus of the 
hypothalamus is an 
integration centre 
between the central 
and peripheral 
autonomic nervous 
systems. In line with 
this role, it is 
characterized by a 
very complex 
architecture and is 
involved in 
numerous functions, 
from stress to the 
Figure 10. The extent and placement of microinjections into the PVH. 
A, Dark-field photomicrograph showing the location and extent of a 
microinjection into the region just dorsal to the PVH (arrow). B, 
Enlarged view of injection site showing that the gradient of diffused 
injectate spreads to involve the PVH. C, Bright-field 
photomicrographs of immunoperoxidase preparations (for Fos-IR) to 
show representative microinjection cannula placements in rats 
injected with saline (C), glutamate (C′) or norepinephrine (C"). 
Magnifications: A, 8.5×; B, 70×; C, 25×. cc, Corpus callosum; Ctx, 
cerebral cortex; fx, fornix; HF, hippocampal formation; ic, internal 
capsule; och, optic chiasm; ot, optic tract; SCh, suprachiasmatic 
nucleus (Cole & Sawchenko, 2002). 
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control of feeding, body energy balance, blood pressure, heart rate and sexual 
activity [89]. 
Physical stress and cytokines have been shown to increase the secretion of 
corticotropin-releasing factor (CRF) by the paraventricular nucleus of the 
hypothalamus (PVN) [90]. 
The paraventricular hypothalamic nucleus is a key site for marshalling integrated 
and adaptive responses to stress. The PVN houses (1) parvocellular neurosecretory 
neurons expressing corticotropin-releasing factor (CRF) for the initiation of the 
endocrine (pituitary–adrenal) arm of the generalized stress response, (2) neurons 
projecting to central autonomic cell groups, including sympathetic preganglionics 
that constitute the neural arm of the stress response, and (3) magnocellular 
neurosecretory cells that release oxytocin and arginine vasopressin (AVP) from 
the posterior pituitary in response to more specific physiological [91]. 
1.3.7.2 Dorsomedial hypothalamus: Cardiovascular response to 
emotional fear 
Shown to play a key role in the cardiovascular changes associated with emotional 
or exteroceptive stress, the DMH may represent a higher order hypothalamic 
center responsible for integrating autonomic, endocrine and even behavioural 
responses to emotional stress [92]. 
Muscimol is an agent found to be inhibitory to virtually all mammalian neurons 
by virtue of its GABA-a receptor agonist properties. Microinjection of muscimol 
has come to be a standard technique to achieve acute reversible suppression of 
neuronal activity in a discrete region of the brain. Treatment in the DMH with 
muscimol was found to dramatically reduce the number of Fos positive neurons 
in both subregions of the PVN [92]. Inhibition of DMH was found to result in 
inhibition of PVN (stress response).  Stress response behaviour observed by 
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stimulation of the DMH included increase of respiratory rate, heart rate and 
arterial pressure [92]. 
 
1.3.7.3 Ventromedial hypothalamus: Regulation of circulatory 
system and food intake 
Neural activity in the VMH has been found to be associated with suppression of 
the circulatory system in rats. Blood pressure and heart-rate were found to 
correlate negatively with activity of the VMH during anaesthesia [93]. 
Stimulation studies show that electrical stimulation of the ventromedial 
hypothalamus (VMH) causes a reduction in food intake, whereas electrolytic or 
chemical lesions in this area result in hyperphagia and obesity in the rat [94]. The 
ventromedial hypothalamic nucleus (VMH) is also necessary for the integrated 
hormonal response to hypoglycemia, as the VMH is sensitive to hypoglycemia for 
full neuronal activity of catecholamine and glucagon secretion and is a key glucose 
sensor for hypoglycemic counter-regulation [95]. 
1.3.8 Nucleus accumbens: Learning, fear and motivation 
Several lines of evidence suggest that the nucleus accumbens (NAcc) may play an 
important role in relating reward processes to the action–outcome associations that 
underlie instrumental learning [96; 97] [98]. The nucleus accumbens, an area 
primarily involved in motivation also forms an integral part of the fear-processing 
circuit, as it receives projections from both the anterior cingulate and the 
basolateral amygdala (BLA). Pietersen et al. found sustained anxiety responses 
that persist beyond the immediate threat are mediated, at least in part, by structures 
such as the nucleus accumbens [99]. 
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The NAcc itself is a 
heterogeneous 
structure and can be 
further divided into 
anatomically distinct 
core and shell 
subregions [100]. 
 
 1.3.8.1 Accumbens core: Learning, fear and directing action 
toward reward 
The core region plays a key role in selecting or initiating actions based on the 
reward value of their consequences. Core-lesioned animals show reduced rates of 
acquisition learning and response. The core appears to be involved in mediating 
the impact of evaluative processes via which animals encode the incentive value 
of the instrumental outcome on the performance of goal-directed actions [98]. 
Ketamine anaesthesia was shown to lead to suppression of c-Fos expression 
associated with drug reward, eliminating perception of reinforcing effects [101]. 
1.3.8.2 Accumbens shell: Anticipation of reward/fear and 
motivation 
The second network involving the accumbens shell, appears to be involved in 
mediating the excitatory effects of stimuli that anticipate reward on goal-directed 
performance [98]. Lesions of the shell have been found to attenuate lever pressing 
for stimuli paired previously with reward [102]. The shell of the accumbens is a 
central structure through which feedback from cues associated with reward help 
to activate and guide actions that are instrumental to gaining access to basic 
commodities. 
Figure 11. Schematic representation of excitotoxic lesions of the 
NAC core (A) and shell (B) (Corbit et al., 2001). 
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The shell region may mediate the impact of stimulus–reward associations on 
instrumental performance, and be responsive to signals for reward [98]. 
1.3.8.3 Ventral tegmental area: Reward/fear expression and 
startle response 
The ventral tegmental area is a group of dopaminergic and glutaminergic neurons 
that work with the accumbens, stimulated during reinforcement or fear learning 
and reward-seeking. Studies show evidence of reinforcing effects produced by 
microinjection of morphine into the VTA [103], suggesting the reinforcing 
property of opiates may be mediated by neural pathways originating in the VTA 
[104]. 
Nicotinic acetylcholine receptors (nAChRs), especially those located in the ventral 
tegmental area, are important in mediating the stimulatory, dopamine enhancing 
and reinforcing effects of ethanol [105]. 
Lesions also produced 
suppressed fear expression 
during conditioned startle 
response experiments, 
suggesting the role of the 
VTA in regulating levels of 
aversive emotional arousal 
[106]. 
  
Figure 12. Coronal rat brain sections showing the probe 
placements (illustrated by vertical lines) in the nucleus 
accumbens and the ventral tegmental area of rats. The 
numbers in each brain section indicate millimetres from 
bregma (Larsson et al., 2005). 
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2. Aim
 
 
As ketamine promotes effective analgesia but also induces undesirable effects, 
there is an ongoing search for novel analogues whose beneficial effects are 
potentiated. To examine the functional properties of a novel ester-analogue of 
ketamine, R5, that has a potentially beneficial profile as indicated by 
preliminary studies, brain activation and select behavioural parameters in rat 
animal models are investigated. 
 
2.1 Specific aims:  
1. Investigate brain activation patterns following administration of 
ketamine and ester-analogues, by employing immunohistochemical detection of 
an immediate-early gene product, c-Fos. 
2. c-Fos immunoreactivity showed significant changes in neuronal activity 
of brain regions associated with nociception and addiction, including the AIC 
and PVN. R5 produced a somewhat similar pattern of activity as ketamine, 
whereas more profound differences in c-Fos were detected after R1. 
Therefore, in the subsequent set of experiments, effects of R5 on pain- and 
addiction-related behavioural parameters were investigated. 
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3. Methodology 
 
 
3.1 Identify which areas of the animal brain show significant 
differences in immunoreactivity patterns between treatment 
groups 
c-Fos staining has been used as a reliable method of quantifying neuronal activity 
[107]. c-Fos is a proto-oncogene that is expressed within dopaminergic neurons 
following depolarization. The protein product, c-Fos protein, can be identified by 
immunohistochemical techniques. Therefore, c-Fos expression can be used as a 
marker for neuronal activity throughout the neuraxis following peripheral 
stimulation. A thorough review found this procedure as an effective method of 
quantifying recent neuronal activity in dopaminergic neurons [108]. Therefore, by 
analysing the brain tissue of rats infused intravenously with different anaesthetics, 
the pathways underlying the effects of those anaesthetics may be better understood. 
Also, the neuroendocrine bases of adverse side-effects can be better understood, 
and anaesthetic chemicals can be refined to avoid post-anaesthesia adverse 
reactions.  
In this study, we intravenously infused ketamine as well as two new anaesthetics, 
dubbed R1 and R5, into the tail vein of rats over the course of 45 minutes and 
subsequently analysed the brain tissue of these rats for the presence of the 
immediate early gene product, c-Fos. 
All experiments were undertaken at the University of Waikato Animal Facility 
(E2.26). Ethical approval was obtained from the University of Waikato Animals 
Ethics Committee for all experiments: 
# 965: Effects of novel intravenous anaesthetics on rat brains, 2015. 
#1020: Exercise addiction withdrawal scoring, 2017.  
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3.1.1 Animal Preparation  
Twenty-two adult female Sprague Dawley rats of 4 months old and weighing 
267.8 +/- 28.8g were studied. Rats were single-housed in standard rat cages with 
fresh wood-shaving bedding and ad libitum access to standard chow (Diet 86, 
Sharpes Stockfeed Ltd) and water unless stated otherwise.  
On the experimental day, rats were atraumatically restrained in perspex tube with 
tail port. Venous cannulation of the marginal tail vein was undertaken and secured 
before animals were returned to their home cage. Rats were randomly assigned to 
one of four treatment groups: 1) control (saline) 2) ketamine, 3) R1 (SN 35210), 
and 4) R5 (SN 35563).  
Ketamine (Hospira Australia Pty Ltd, Australia) was administered at 10mg/ml 
diluted in 0.9% saline solution. R1 and R5 were synthesised by the Auckland 
Cancer Society Research Centre, Auckland, New Zealand, and solubilized in 0.9% 
saline at 10mg/ml prior to administration. 
 
3.1.2 Drug administration  
Mini-bore intravenous tubing was attached to the venous cannula of the tail vein 
for drug administration. For the purposes of this study loss of righting reflex (the 
ability of the animal to spontaneously right from a position of dorsal recumbancy 
to a position of sternal recumbancy - LORR) served as the key measure of sedation. 
Control animals received an intravenous infusion of 0.9% saline solution at 0.4 
ml/kg/min for 45 minutes. 
Ketamine group animals received intravenous ketamine (10mg/ml) infusions 
initially at 20mg/kg/min until LORR, and thereafter at 2mg/kg/min to 45 minutes. 
R1 group animals received intravenous R1 (10mg/ml) initially at 20mg/kg/min 
until LORR, and thereafter at 4mg/kg/min to 45 minutes. 
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R5 group animals received intravenous R5 (10mg/ml) infusions initially at 
20mg/kg/min until LORR, and thereafter at 4mg/kg/min to 45 minutes. 
Infusions of ketamine, R1, and R5 were titrated in an up-and-down fashion to 
maintain a consistent level of sedation (defined by maintained LORR) for the 
duration of drug infusions.  
Infusion rates in ketamine treated animals trended downwards from the initial 
20mg/kg/min due to developing respiratory depression. Conversely infusion rates 
in the R1 and R5 treated groups were increased from the initial 4mg/kg/min due 
to lightening of sedative effect.  
Following completion of drug infusions all animals were maintained in their home 
cages for a period of 15 to 30 minutes. Time to return of righting reflex (the time 
from cessation of drug infusion to first spontaneous righting) was recorded. At 60 
to 75 minutes following commencement of study drug injection animals 
underwent perfusion and brain dissection. 
3.1.3 Perfusion/brain dissection 
An hour after drug administration, animals were anesthetised with urethane (35% 
dissolved in 0.9% saline, 3mL, intraperitoneally (i.p.) administered), and perfused 
rapidly through the aorta with 50 ml of saline followed by 500 ml of 4% 
paraformaldehyde in 0.1 phosphate buffer (pH 7.4) . Brains were removed and 
post-fixed overnight in the same fixative at 4°C. 60µm thick coronal vibratome 
sections of the brain were processed as free-floating sections for standard single 
antigen immunostaining of c-Fos. Sections were rinsed in 50 nM TBS (pH 7.4–
7.6), and then pre-treated for 10 min in 3% H2O2, 10% methanol (diluted in TBS). 
After rinsing in TBS they were further incubated overnight at 4°C in the primary 
rabbit-anti-Fos antibody (diluted  1:40 000; Synaptic Systems, Australia) washed 
in TBS, and subsequently incubated for 1h at room temperature in the secondary 
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goat-anti-rabbit antibody (1:400; Vector Laboratories). Following four washes in 
TBS, sections were incubated for 1h with avidine–biotin peroxidase complex 
(1:800; Elite Kit, Vector Laboratories). The vehicle for all incubations was a 
solution of 0.25% gelatin and 0.5% Triton X-100 in TBS. The peroxidase in the 
tissue was visualized with 0.05% diaminobenzidine (DAB), 0.01% hydrogen 
peroxide and 0.3% nickel sulfate (12-min incubation). Sections were washed in 
TBS to stop the reaction, mounted onto gelatin-coated slides, air-dried, dehydrated 
in ascending concentrations of ethanol, soaked in xylene (Merck KGaA, Germany) 
and embedded in Entellan (Merck KGaA, Germany).  The number of Fos-positive 
nuclei was counted bilaterally for each neuroanatomical region of interest using 
ImageJ Software and manual counting, with boundaries defined according to the 
atlas [110], on 2–4 sections per animal. Images provided by a CCD camera 
attached to a Nikon Eclipse 400 microscope were analysed using Nikon NIS 
Elements image software.  Densities of Fos-immunoreactive nuclear profiles (per 
1 mm) were averaged per animal, and then per experimental group. Statistical 
analysis of data was performed using ANOVA followed by Bonferroni’s post-hoc 
test and Fisher analysis, and values were considered significantly different when 
p<0.05 [111]. 
Based on the differences in immunoreactivity patterns, we were then able to 
conduct select behavioural studies during direct administration to regions showing 
significant changes to further examine these effects. This included testing of 
analgesic effects and co-administering the drug with an ion-channel blocker to 
investigate the mechanism of action for effective analgesia. 
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3.2 Investigate the behavioural effects of ketamine-analogues 
directly administered in pain and addiction pathways. 
In the investigation 
into the action of 
drugs on specific 
brain regions, the 
method of direct 
injection into brain 
sites of interest is a 
widely used 
approach. This 
allows site-specific 
direct 
administration of a 
chemical to the region hypothesised to mediate a behaviour, allowing 
confirmation and measurement of the underlying role of a region. Using 
stereotaxic equipment, this can be performed quickly and humanely under 
anaesthetic surgery, and allows repeated administration for months after [109]. 
 
Approximately 12-week old, female Sprague Dawley rats received site-specific 
intracranial injections aimed at one of 3 sites of interest using coordinates from 
The Rat Brain Atlas [110]: 
Table 1. . Coordinates for cannulation of the different brain sites used in this study. Coordinates 
measured in relation to bregma. AP: anterior-posterior; L: lateral; DV: dorsal-ventral 
Area:     AP:     L:      DV: 
PVN -2.5 0.0 -8.1 
AIC 3.0 4.0 -5.5 
ICV -1 1.5 -3.5 
Figure 13. Schematic representation of cannula implantation (I) and 
anchoring screws (II, III), on rat skull (Gispen et al., 1979). 
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3.2 A. Description of surgical procedure 
1. Anaesthesia:   
Ketamine (90 mg/kg) and xylazine (10 mg/kg) were administered i.p., with 
supplements of approximately 1/3 of this dose if depth of anaesthesia was 
insufficient. Prior to the initiation of the surgery, anaesthetic depth was confirmed 
by absence of toe-pinch and tail-pinch reflex. This procedure was repeated 
approximately every 10 – 15 min throughout the surgery. In case of an observed 
toe-pinch reflex prior to the beginning of surgery, an additional 5 – 10 min waiting 
time was given to allow the anaesthetic to produce its full effect.  A supplemental 
anaesthetic injection was given if the reflex was still present 15 min after the initial 
injection. If a visible response was observed once the procedure began, the 
procedure was stopped, and a supplemental injection of ketamine/xylazine was 
given (see above).  The procedure was resumed when the toe-pinch reflex was no 
longer observable. 
2. Intracranial cannula implantation:   
Under ketamine/xylazine anaesthesia, rats were mounted into a stereotaxic 
instrument.  The scalp was shaved, scrubbed with betadine and alcohol, and dried. 
Using aseptic technique, a small midline incision was made to expose the skull 
surface. The surface was cleaned of blood and allowed to dry (to make surface 
landmarks more visible). Skull landmarks (bregma and lambda) were noted and 
coordinates for cannula placement sites measured (based on the rat brain atlas of 
[110]).  
Three to 4 small holes were drilled in the skull and the surface was again cleaned 
of blood, after which a 22 gauge stainless steel unilateral or bilateral guide cannula 
(Plastics One, Inc.) was lowered into the appropriate hole to the pre-determined 
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depth; stainless steel self-tapping screws were placed into the other holes to act as 
anchors.  Acrylic dental cement was applied to the screws and cannulas to bind all 
together after drying.  Sutures were placed at each end of the incision, and the 
animal was removed from the instrument. The cannula placement surgery itself 
was generally completed within 20-25 minutes. 
3. Aseptic technique:  
Instruments were sterilized via autoclave at least one day before a surgery day.  
Each pack was marked with autoclave indicator tape.  Because multiple rats 
typically undergo surgery on any given surgery day, the tips of the instruments 
were re-sterilized between rats with the following sequence:  immersion of the tips 
into hydrogen peroxide, followed by immersion in 70% isopropyl alcohol.  This 
typically removes any blood or other debris on the tips and sterilizes them.   
The scalp was shaved, scrubbed with betadine and alcohol, and dried.  Using 
aseptic technique, a small midline incision was made to expose the skull surface, 
and the cannula was implanted as described above.  Lab coats, sterile gloves and 
a mask were used during surgery. 
4. Surgery recovery and post-op care  
After surgery, bacitracin ointment was applied to the external wound; carprofen 
was given (5mg/kg) as a post-operative analgesic.  Carprofen was also 
administered on the day following surgery (same dose).  The animal was kept 
warm and observed frequently until arousal and self-righting movement was 
regained (usually approximately 60 minutes after removal from stereotaxic frame).  
The animal was returned to its cage and maintained on ad lib food and water for 7 
- 10 days before any further manipulations were done (except handling).  Rats 
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were weighed and inspected daily for at least 3 days for any signs of illness, 
including weight loss, improper wound healing, sluggishness and poor grooming. 
Rats were allowed to recover for one week while housed in standard cages in the 
animal facility prior to testing.  
3.2 B. Manipulations 
The first behavioural study tested the analgesic effect of R5 administered 
directly to the nociception area of the brain, compared to saline. 
 
1. Anterior insula cortex: Tail flick evaluation   
Animals: 
Twelve bilaterally cannulated adult female Sprague Dawley rats (age 147 +/- 
9days; weight 239 +/-31g) were studied. 
Intracranial injections:  
Bilateral cannulation with two 26-gauge cannula into the anterior insular cortex 
with coordinates as described in Table 1. 
Drug administration: 
For intracranial injections, solutions were loaded into 30-cm lengths of PE-50 
tubing attached to 10-µl Hamilton syringes. Drug/saline injection was delivered 
by 1.0 µl bolus over 30 seconds. Control animals (n=6) received 0.9% saline 
solution at 1µl, and test animals (n=6), R5 (SN 35563) concentration 10mg/ml at 
1 µL. 
Tail Flick evaluation: 
A tail flick analgesia meter (Colombus Instruments, Colombus, Ohio) was used to 
determine pain sensitivity in the control and drug treated animals. Radiant heat 
was applied using a shutter-controlled lamp as a heat source focused on a spot 
located 6-8cm from the tip of the tail. The intensity of the beam was set at a level 
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producing basal latency times between 3 and 4.5 seconds. To prevent thermal 
tissue injury the cut off time as set at 10 seconds. A digital response time indicator 
with a resolution of 0.1s measured the time from initiation of stimulus until tail 
withdrawal (tail flick). This measurement was repeated with all animals every 5 
minutes for 60 minutes in total. 
 
The tail-flick latency (TFL) response following infusion of control and study drugs 
was calculated as a percentage of the maximum possible effect (MPE) such that: 
 
%MPE = [TFL (post-drug) – TFL (pre-drug) / 10 sec – TFL (pre-drug)] × 100% 
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3. Intracerebroventricle: Tail flick evaluation 
In an attempt to further investigate the mechanism of action by which R5 produces 
analgesic effects, a second behavioural study administered R5 directly to the HPA-
axis by ICV injection, preceded by barium chloride administration. This aimed to 
test the hypothesis that barium blocks two-pore potassium (K2P) ion channels in 
neuronal membranes required for analgesic effects of anaesthetics. 
 
Animals: 
Nine unilaterally cannulated adult female Sprague Dawley rats (age 147 +/- 9days; 
weight 239 +/-31g) were studied.  
Intracranial injections:  
Implanted unilaterally (right) with one 26-gauge cannula into the anterior horn of 
the lateral ventricle with coordinates as described in Table 1. 
Cannulas were held in place with dental cement, and patency maintained with 
occlusive stylets.  
Drug administration: 
For intraventricular injections, solutions were loaded into 30-cm lengths of PE-50 
tubing attached to a 10-µL Hamilton syringe prefilled with test agents. All 
injections were delivered by 1.0 µL bolus over 30 seconds. Stock solutions of 
NaCl 0.9% (control), BaCl2 10mg/mL (test), and R5 (SN 35563) 10mg/mL were 
prepared.  
Tail Flick evaluation: 
A tail flick analgesia response was measured as above. 
Test algorithm: 
Following assessment of baseline tail flick latency (time 0) rats underwent 
interventricular injection of 1µL saline (control [n=4]) or 1 µL barium chloride 
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(test [n=5]) at time equals 2 minutes. TFL was reassessed at 3 minutes. Further 
1µL injections of saline or barium solutions were undertaken at 5 minutes, and 
followed immediately by interventricular injection of R5 (SN 35563) at 1µL. TFL 
evaluation was undertaken at 1 minute intervals from time 6 minutes to 10 minutes, 
then at 5 minute intervals thereafter to 60 minutes. 
Statistical analysis: 
Statistical analysis of all variables was undertaken using RMANOVA. 
 
3. Paraventricular nucleus of the hypothalamus: Exercise 
withdrawal 
Finally, as the nociception system is also involved in addiction and withdrawal 
behaviour, the effect of R5 in reducing addictive-like, exercise-induced 
withdrawal symptoms was investigated. This was achieved by direct 
administration of R5 to the PVN after addictive-like, exercise-induced 
withdrawal, before behavioural effects were scored and compared. 
 
Animals: 
After recovery from cannulation, 16 rats were housed in running wheel chambers 
for one week to habituate, then assigned to one of two groups for one week: 
- Food restricted to 1hr per day (n=8) 
- Free (ad libitum) access to food (n=8) 
During this period, food intake and weight was monitored daily.  After this period, 
rats were administered 1.0 mg/kg naltrexone via i.p. (opioid blocker) to induce 
opioid withdrawal effects, in the morning at the time that they are normally given 
food access, followed by the site-specific administration of an anaesthetic agent 
via cannula. 
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The following anaesthetics and doses were used: 
1. R5 (SN35563): 10µg/µL, 1µL 
2. Saline (control): 0.9% solution, 1µL 
Intracranial injections: 
The stylet (or dummy cannula) was removed and replaced by an injection cannula 
with a 1 mm protrusion beyond the tip of the guide cannula. The injection cannula 
was connected via PE tubing to of 10-µl Hamilton syringes prefilled with either 
R5 or saline, and a volume of 0.5 microliters/side was injected over a period of 
approximately 60 seconds. The injector was left in place for another 30 seconds 
to allow the injected substance to diffuse into the tissue. To minimize stress, the 
animal was placed in a small cage during this 2 minute period. The injector was 
then removed, the stylet replaced, and the rat was then placed in a transparent 
observation chamber. 
Behavioural Scoring: 
Withdrawal symptoms were then recorded by behavioural scoring over a one hour 
period, before being returned to running wheel cages in the animal facility. 
Withdrawal behaviours observed were scored in accordance with [112] in 2 ways:  
1) body weight loss in 1 hr (1 for every 1% of weight loss), wet dog shakes (1-2 
shakes = 2; 3 or 4 shakes = 3; 4 or more shakes = 4), escape attempts (2-4 attempts 
= 1, 5 to 9 attempts = 2, and 10 or more attempts = 3) 
2) Abnormal posture/writhing, teeth chattering, ptosis (drooping eyelids), 
diarrhoea, profuse salivation, swallowing movements, abnormal postures, and 
chromodacyorrhea (red tears) were scored for their presence 
The total withdrawal scores were calculated as the sum of all of the individual 
withdrawal scores. 
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Following each injection, the animals received 2 days of ad libitum access to food, 
followed by 2 days of restricted access to food for those animals that were in the 
food restricted group, which means that animals received one naltrexone and one 
site-specific treatment injection every 4 days. In total each animal received 2 
treatments and naltrexone administrations over 6 weeks.  
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4. Results 
 
4.1 Identify which areas of the animal brain show significant 
differences in immunoreactivity patterns between treatment 
groups. 
All animals receiving sedative drug infusion displayed rapid onset sedation 
characterised by loss of righting reflex. Return of righting reflex time was 
significantly greater in the ketamine group when compared with the R1 (SN 35210) 
group (p=0.0079), and the R5 (SN35563) treated group (p=0.0079). One animal 
from the ketamine and R1 (SN 35210) group died on induction of anaesthesia 
following inadvertent drug overdose.  
Administered drug doses in conjunction with behavioural metrics are presented in 
Table 2. 
Table 2. Anaesthetic drug dosing and behavioural metrics. 
 Control      
(n=5) 
Ketamine   
(n=5) 
SN 35210   
(n=5) 
SN 35563   
(n=5) 
Time to 
LORR (sec) 
NA 63.0 
 (56-72.5) 
66.0              
(49.5 – 69.5) 
70.0             
(55.5 – 87.5) 
Dose to 
LORR 
(mg/kg) 
NA 21.0              
(18.7 – 24.2) 
22.0             
(19.8 – 23.2) 
23.3              
(18.5 – 29.2) 
Total dose 
(mg/kg) 
NA 95.0             
(92.5 – 103) 
221               
(201 – 237) 
203                
(198 – 209) 
Time to 
RORR (sec) 
NA 613                
(593 – 776) 
45.0                 
(29.5 – 56.0) 
70.0              
(55.5 – 87.5)  
 
All data median (IQR) 
LORR: loss of righting reflex 
RORR: return of righting reflex 
 
c-Fos Analysis 
c-Fos immunoreactivity showed differences in patterns of neuronal activity 
between ketamine and novel analogues. Novel ketamine-analogues produced 
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Figure 14. Both R1 and R5-treated animals show significantly (**) reduced neuronal activity in 
the anterior insular cortex when compared to saline. ** = p< 0.01 
somewhat different patterns of activity than ketamine, with R5 producing more 
profound differences than R1. 
 
4.1.1 Anterior insula cortex:  
In the AIC, c-Fos immunoreactivity following both R1 and R5 infusion was 
significantly inhibited compared to saline but not ketamine treatment, while 
ketamine infusion did not show a significant effect on c-Fos immunoreactivity 
(Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
** ** 
Figure 15. c-Fos immunoreactivity in the anterior insular cortex 
of animals treated with saline and R5. 
55 
 
4.1.2 Area postrema: 
No significant changes in c-Fos immunoreactivity in the AP were observed 
between saline and any of the administered anaesthetics (Figure 16.) 
 
 
 
Figure 16. Neuronal activity did not differ significantly in animals treated with the different drugs 
in the AP. 
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4.1.3 Nucleus of the solitary tract: 
R1-treated animals show significantly (**) increased c-Fos immunoreactivity 
compared to saline-treated animals in the NTS, and R5-treated animals show 
significantly (*) increased c-Fos immunoreactivity in this region compared to 
saline-treated animals. Ketamine infusion did not show a significant effect on c-
Fos immunoreactivity (Figure 17). 
 
 
 
 
 
 
  
Figure 17. R1-treated animals show significantly (**) increased neuronal activity compared to 
saline-treated animals in the NTS, and R5-treated animals show significantly (*) increased 
neuronal activity compared to saline-treated animals. * = p<0.05, ** = p<0.01 
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4.1.4 Bed nuclei of the stria terminalis: 
No significant changes in c-Fos immunoreactivity were observed in the BNST 
compared to saline- or ketamine-treated animals (Figure 18). 
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Figure 18. No significant changes were observed in neuronal activity in the BNST compared to 
saline-treated animals. 
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4.1.5 Basolateral amygdala: 
R1-treated animals show significantly reduced c-Fos immunoreactivity in the 
BLA compared to both saline-treated (***), and ketamine-treated (**) animals 
(Figure 19).  
 
 
 
 
  
Figure 19. R1-treated animals show significantly reduced neuronal activity in the BLA compared 
to both saline-treated (***), and ketamine-treated (**) animals. **=p<0.01, ***=p<0.001 
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4.1.6 Central nucleus of the amygdala: 
R1-treated animals show significantly (*) increased c-Fos immunoreactivity in the 
CeA compared to saline-treated animals, and R5-treatement significantly (**) 
increased c-Fos immunoreactivity in this region compared to saline administration 
(Figure 20). 
 
 
 
 
 
 
  
Figure 20. R1-treated animals show significantly (*) increased neuronal activity compared to 
saline-treated animals in the CeA, and R5-treatement significantly (**) increased neuronal 
activity in this region when compared to saline administration. * = p<0.05, ** = p<0.01 
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4.1.7 Caudate putamen: 
Both ketamine- and R1-treated animals show significantly (*) increased c-Fos 
immunoreactivity in the CPu compared to saline treatment, while R5-treated 
animals show significantly (*) reduced c-Fos immunoreactivity in this region 
compared to ketamine treatment (Figure 21). 
 
 
 
 
 
 
 
  
  
Figure 21. Both ketamine- and R1-treated animals show significantly (*) increased neuronal 
activity in the CPu compared to saline treatment. R5-treated animals show significantly (*) 
reduced neuronal activity in this region when compared to ketamine treatment. * = p<0.05 
Figure 22. c-Fos immunoreactivity in the caudate putamen of 
animals treated with saline and ketamine. 
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4.1.8 Paraventricular nucleus of the thalamus: 
Ketamine administration resulted in significantly (***) increased c-Fos 
immunoreactivity in the PVT compared to saline administration. Saline-, R1- 
and R5-treated animals all show significantly (***) reduced c-Fos 
immunoreactivity of this region when compared to ketamine (Figure 23).  
  
  
Figure 23. Ketamine administration resulted in significantly (***) increased neuronal activity in 
the PVT compared to saline administration. Saline-, R1- and R5-treated animals all show 
significantly (***) reduced neuronal activity of this region when compared to ketamine. * = 
p<0.05, ** = p<0.01, *** = p<0.001 
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4.1.9 Paraventricular nucleus of the hypothalamus: 
R5-treated animals show significantly (***) reduced c-Fos immunoreactivity in 
the PVN, and ketamine-treated animals show significantly (**) reduced c-Fos 
immunoreactivity in this region when compared to saline. R1-treated animals 
show significantly (***) increased c-Fos immunoreactivity, and R5-treated 
animals show significantly (**) increased c-Fos immunoreactivity in this region 
compared to ketamine-treated animals (Figure 24). 
 
  
  
Figure 24. R5-treated animals show significantly (***) reduced neuronal activity in the PVN, and 
ketamine-treated animals show significantly (**) reduced neuronal activity in this region when 
compared to saline. R1-treated animals show significantly (***) increased neuronal activity, and 
R5-treated animals show significantly (**) increased neuronal activity in this region compared 
to ketamine-treated animals. * = p<0.05, ** = p<0.01, *** = p<0.001 
 
Figure 25. c-Fos immunoreactivity in the paraventricular 
nucleus of animals treated with saline and ketamine. 
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4.1.10 Dorsomedial nucleus of the hypothalamus:   
Both ketamine- and R5-treated animals show significantly (***) increased c-Fos 
immunoreactivity in the DMH, and R1-treated animals show significantly (*) 
increased c-Fos immunoreactivity in this region when compared to saline 
treatment. R1-treated animals show significantly (***) reduced c-Fos 
immunoreactivity in this region when compared to ketamine treatment (Figure 
26). 
 
 
 
 
  
Figure 26. Both ketamine- and R5-treated animals show significantly (***) increased neuronal 
activity in the DMH, and R1-treated animals show significantly (*) increased neuronal activity in 
this region when compared to saline treatment. R1-treated animals show significantly (***) 
reduced neuronal activity in this region when compared to ketamine treatment. * = p<0.05, ** = 
p<0.01, *** = p<0.001 
64 
 
4.1.11 Ventromedial hypothalamus: 
Saline-, R1- and R5-treated animals all show significantly (***) reduced c-Fos 
immunoreactivity in the VMH compared to ketamine treatment. R5-treated 
animals show significantly (***) reduced c-Fos immunoreactivity in this region 
when compared to saline treatment (Figure 27). 
 
 
  
Figure 27. Saline-, R1- and R5-treated animals all show significantly (***) reduced neuronal 
activity in the VMH compared to ketamine treatment. R5-treated animals show significantly 
(***) reduced neuronal activity in this region when compared to saline treatment. *** = 
p<0.001 
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4.1.12 Nucleus accumbens core: 
R5-treated animals show significantly (***) increased c-Fos immunoreactivity in 
the AcbC, and ketamine-treated animals show significantly (**) increased c-Fos 
immunoreactivity in this region compared to saline treatment. R1-treated animals 
show significantly (*) reduced c-Fos immunoreactivity compared to ketamine 
(Figure 28). 
 
 
 
 
 
  
Figure 28. R5-treated animals show significantly (***) increased neuronal activity in the AcbC, 
and ketamine-treated animals show significantly (**) increased neuronal activity in this region 
compared to saline treatment.R1-treated animals show significantly (*) reduced neuronal 
activity compared to ketamine. * = p<0.05, ** = p<0.01, *** = p<0.001 
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4.1.13 Nucleus accumbens shell:  
Ketamine-treated animals show significantly (**) increased c-Fos 
immunoreactivity in the AcbSh compared to saline treatment. Both R1- and R5-
treated animals show significantly (***) reduced c-Fos immunoreactivity 
compared to ketamine treatment (Figure 29). 
 
 
 
  
Figure 29. Ketamine-treated animals show significantly (**) increased neuronal activity in the 
AcbSh compared to saline treatment. Both R1- and R5-treated animals show significantly (***) 
reduced neuronal activity compared to ketamine treatment. ** = p<0.01, *** = p<0.001 
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4.1.14 Ventral tegmental area:  
Both ketamine- and R1-treated animals show significantly (***) increased c-Fos 
immunoreactivity in the VTA, and R5-treated animals show significantly (**) 
increased c-Fos immunoreactivity in this region when compared to saline 
treatment. Saline-treated animals show significantly (***) reduced c-Fos 
immunoreactivity in the VTA, and R5-treated animals show significantly (*) 
reduced immunoreactivity in this region when compared to ketamine treatment 
(Figure 30). 
 
  
Figure 30. Both ketamine- and R1-treated animals show significantly (***) increased neuronal 
activity in the VTA, and R5-treated animals show significantly (**) increased neuronal activity in 
this region when compared to saline treatment. Saline-treated animals show significantly (***) 
reduced neuronal activity in the VTA, and R5-treated animals show significantly (*) reduced 
neuronal activity in this region when compared to ketamine treatment. * = p<0.05, ** = p<0.01, 
*** = p<0.001 
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4.2 Investigate the behavioural effects of ketamine-analogues 
directly administered in pain and addiction pathways. 
c-Fos immunoreactivity showed significant changes in neuronal activity of brain 
regions associated with nociception and addiction. Novel ketamine-analogues 
produced somewhat different patterns of activity than ketamine, with R5 
producing more profound differences than R1. 
Based on these differences in immunoreactivity patterns, select behavioural 
studies were conducted, first testing the analgesic effect of R5 administered 
directly to the nociception area of the brain, compared to saline. 
 
4.2.1 AIC - Tail flick  
Direct bilateral injection of R5 into the insular cortex resulted in modest attenuated 
pain response in rats. 
Raw and %MPE tail flick responses are presented graphically in figures 34 & 35 
respectively. 
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Figure 31. AIC raw tail flick response data. Direct bilateral injection into the insular cortex of R5-
treated animals show modest attenuated tail flick response compared to saline-treated animals. 
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Figure 32. AIC tail flick % MPE data. Direct bilateral injection into the insular cortex of R5-treated 
animals show modest attenuated tail flick response compared to saline-treated animals 
 
4.2.2 Intracerebroventricle (ICV) - Tail flick 
In an attempt to further investigate the mechanism of action by which R5 produces 
analgesic effects, a second behavioural study administered R5 directly to the HPA-
axis by ICV injection, preceded by barium chloride administration. This aimed to 
test the hypothesis that barium blocks two-pore potassium (K2P) ion channels in 
neuronal membranes required for analgesic effects of anaesthetics. 
 
Interventricular injections of saline and R5 (SN 35563) were well tolerated. 
Interventricular injection of barium chloride resulted in mild irritation in all test 
animals.  
Barium chloride (BaCl) injection into the ICV preceding R5 anaesthetic 
administration into the same site, is shown to inhibit the analgesic effect of R5, 
resulting in reduced tail flick latency responses, when compared to sodium 
chloride (NaCl)-treated animals. 
The results show a marked decrease in tail flick response time (6s to 3s), up to 
8mins after administration of barium chloride and R5, when compared to saline 
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and R5. After the 8min mark, barium chloride appears to be metabolized and 
begins to show similar behavioural responses between groups. 
Raw TFL responses and TFL as %MPE are presented in figures 36 & 37 below. 
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Figure 33. ICV raw tail flick responses according to group.  
BaCl-treated animals show clearly reduced response times when compared to saline-treated 
animals.  Data: mean (SEM). Dotted lines represent saline/barium injection. Solid line represents 
SN 35563 injection. 2-way RMANOVA p=0.0006; max difference at 6,7,8,9 minutes p<0.001 all. 
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Figure 34. ICV tail flick responses %MPE according to group. BaCl-treated animals show clearly 
reduced response times when compared to saline-treated animals. Data: mean (SEM). Dotted 
lines represent saline/barium injection. Solid line represents SN 35563 injection. 2-way RMANOVA 
p=0.005; max difference at 6,7,8,9 minutes p<0.001 all. 
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4.2.3 PVN - Exercise withdrawal 
Finally, as the nociception system is also involved in addiction and withdrawal 
behaviours, the effect of R5 in reducing addictive-like, exercise-induced 
withdrawal symptoms was investigated. This was achieved by direct 
administration of R5 to the PVN after addictive-like, exercise-induced 
withdrawal, before behavioural effects were examined. 
 
Direct injection of R5 administered to the PVN shows a strong trend (p=0.0592) 
of inhibiting exercise withdrawal behaviour compared to saline-treated animals 
(Figure 35). 
 
  
Figure 35. PVN exercise withdrawal results show a strong trend of R5-treated animals exhibiting 
reduced withdrawal behaviour compared to saline treatment. p=0.0592 
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5. Discussion 
 
5.1 Identify which areas of the animal brain show significant changes 
in activity between treatment groups. 
The present study used novel molecular analogues of ketamine to investigate the 
comparative neuronal activity when administered in rat animal models, with an 
aim to identify novel drugs that influence a similar repertoire of brain targets as 
ketamine, while attenuating the unpleasant side-effects of ketamine use. 
c-Fos immunoreactivity showed significant changes in neuronal activity of brain 
regions associated with these symptoms. Novel ketamine-analogues produced 
somewhat different patterns of activity than ketamine, with R5 producing more 
profound differences than R1. 
5.1.1 Emetic pathway  
AP - Nausea 
No significant changes in neuronal activity of the area postrema, commonly 
associated with emetic (nausea) responses, were observed between saline and 
any of the administered anaesthetics. 
I would encourage repeating this study with a larger sample, as error bars are 
large and the small sample shows some indication of all anaesthetics inhibiting 
nausea activity slightly when compared to saline, with R1 showing inhibition 
more so than the other anaesthetics; a result that would be advantageous in 
refining the common side-effect of nausea after ketamine anaesthesia.  
The small sample sizes seen here are a result of the method of sample collection 
and the anatomical location of this brain region. During vibratome sectioning of 
the fixed brain, the brain is first cut in half and affixed to the slide to fit under 
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the blade, but in this process this small part of the brainstem is often damaged. 
Other methods of sectioning could be utilized in future to overcome this issue. 
 
5.1.2 Nociception pathway  
AIC- Nociception 
Both R1 & R5 show significant inhibition of pain pathways in the agranular 
insula cortex when compared to saline treatment, indicating active analgesia. 
Interestingly however, regular ketamine did not show significant reduction in 
activity of this region when compared to saline, even though we would assume 
analgesia was induced. When compared to ketamine, both R1 and R5 showed 
slightly reduced activity of this region, which may indicate a stronger analgesic 
effect than ketamine. 
Nociception-pathway neuronal activity studies have associated activity in the 
AIC with the subjective evaluation of heat/pain, whereas the posterior insula 
cortex is activated when painful stimulus is applied, regardless of subjective 
evaluation [113]. This may imply that our observation of significantly reduced 
activity in the AIC after administration of R1 and R5, correlates with 
significantly reduced subjective experience of pain. 
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5.1.3 Stress Pathway 
NTS - Peripheral sensory relay center/ cardiovascular response to 
stress 
R1 is shown to produce a significant increase in activity of this region associated 
with regulating sympathetic and cardiovascular systems in response to stress, 
when compared to saline. R5 also produces a significant increase in activity 
when compared to saline, but to a lesser extent than R1. 
This region is associated with control of physiological response, such as food 
intake and stress response. Release of CRH from the PVN during stress, has 
been shown to activate the NTS to regulate sympathetic and cardiovascular 
functions [69].  
Results showing that increased activity in this region when compared to saline, 
after any anaesthetic administration, may signify more activity of the stress 
response circuit than when compared to saline, especially as this correlates with 
results in the PVN and associated areas. This is not overly surprising as one 
would expect any induction of anaesthesia to be slightly more stressful than no 
treatment. 
When comparing the anaesthetics, our results show that the novel ketamine 
analogues R1 and R5 may produce slightly increased activity of this region 
associated with stress response, when compared to regular ketamine, but any 
differences are not significant. 
R1 produced the highest levels of activity in regions associated with response to 
stress, including the PVN. 
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PVN - Stimulating stress response 
Significant inhibition of this region was produced by ketamine and R5, when 
compared to saline. R1 produced significantly (p<0.0001) increased, and R5 
produced significantly (p=0.003) increased neuronal activity of this region 
associated with stimulating stress responses (PVN), when compared to ketamine. 
This may imply that anaesthetic agents inhibit the activity in this region 
associated with stress response, however our data showed that normal ketamine 
inhibits activity in this region more significantly than the novel analogues (R1 
and R5).  
R1 was the least effective anaesthetic agent at inhibiting this region, and perhaps 
the stress response.  
c-Fos analysis showed that R1 also produced the most neuronal activity in the 
NTS region, an associated area implicated in stimulating the stress response. 
Studies have shown that stress factors can influence CRH release in PVN that 
in turn stimulates the NTS to regulate sympathetic and cardiovascular responses 
to stress [69].  This supports the suggestion that R1 may stimulate the stress 
response more than regular ketamine anaesthesia. 
BNST - Anxiety, addiction & stress response 
No significant differences in activity between ketamine and the novel analogues 
were observed, demonstrating that these novel analogues do not significantly 
increase, or reduce activity of the BNST, an anxiety and stress response 
associated region, compared to the currently used ketamine anaesthetic. R1 
produced slightly more neuronal activity of this region than any other treatment, 
though differences were not deemed significant. 
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VMH - Regulation of circulatory system & food intake 
R1, R5 and saline all showed significantly reduced neuronal activity of this 
region associated with reduced circulatory system response compared to 
ketamine.  
Neuronal activity in the VMH has been found to be associated with suppression 
of the circulatory system in rats. Blood pressure and heart-rate were found to 
correlate negatively with activity of the VMH during anaesthesia [93]. 
Neuronal activity levels produced by R1 are similar to that of saline, while R5 
produced significant inhibition of this region when compared to saline, therefore 
implying that R5 may trigger an increase in heart-rate and blood pressure. 
Ketamine seems to produce much greater stimulation of this region, which may 
result in more reduced circulatory responses during ketamine anaesthesia. R5 
however produced significant inhibition of this region, which may imply an 
increase in blood pressure and heart-rate.  
This result correlates with increased activity produced in the NTS by R5 that is 
associated with increased heart-rate in response to stress. 
5.1.4 Arousal pathway 
PVT- Arousal 
Ketamine produced very significantly increased neuronal activity of the arousal-
associated area (PVT), when compared to saline. 
However, both R1 and R5 produced very significantly reduced neuronal activity 
of the arousal-related region (PVT), when compared to ketamine.  
This would imply that the new ketamine analogues (both R1 and R5) may 
produce reduced arousal after anaesthesia, a common emergence reaction upon 
recovering from ketamine anaesthesia. 
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5.1.5 Fear pathway 
BLA - Conditional fear responses 
R1 showed very significantly inhibited neuronal activity in the BLA region, 
responsible for acquisition of fear responses, when compared to saline. R1 also 
shows very significantly reduced neuronal activity of this area, when compared 
to ketamine. 
R1 produced significantly reduced activity of the BLA, which has previously 
been associated with fear behaviour. [77]. This evidence may imply that R1 
produces reduced fear behaviour, when compared to ketamine. The suppression 
of fear behaviour by intra-BLA muscimol (inhibition) has been associated with 
increased c-Fos expression in the central nucleus of the amygdala (CeA). This 
correlates with the observed significant increase in neuronal activity in the CeA 
after administration of R1 also. 
This may illustrate that the novel anaesthetic R1, significantly reduces some 
aspects of fear responses after anaesthetic administration, compared to ketamine 
anaesthesia. This would be advantageous in eliminating the disturbing 
emergence reactions that follow ketamine anaesthesia, often associated with 
fearful responses. 
CeA - Stimulating emotional response 
All anaesthetics showed an increase in activity of this region, responsible for 
emotional responses, when compared to saline.  
Increased activity of the CeA has been associated with suppression of fear 
response [77]. This may imply that all anaesthetics agents tested in the present 
study reduce emotional response, although R5 produced the most significant 
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increase in activity when compared to saline, implying that R5 may suppress 
emotional response significantly. 
When compared to ketamine, both novel analogues appear to produce less 
activity of this region, though any difference was not significant.  
AcbC – Learning, fear and directing action toward reward. 
Both ketamine and R5 produce significantly (P=0.0011 and P=0.0009 
respectively) increased neuronal activity in the AcbC, an area associated with 
motivation and fear, when compared to saline.  
However, R1 produces significantly reduced neuronal activity of this region 
when compared to ketamine, similar to that of saline.  
This may imply that as ketamine and R5 significantly stimulate this region 
associated with fear and motivation, and R1 does not produce this effect, that 
R1 does not produce increased fear responses observed during ketamine 
anaesthesia. 
The nucleus accumbens, an area primarily involved in motivation also forms an 
integral part of the fear-processing circuit, as it receives projections from both 
the anterior cingulate and the basolateral amygdala (BLA). This correlates with 
the lack of neuronal activity produced by R1 in the BLA, where both ketamine 
and R5 also significantly increased activity.  
This reinforces the view that R1 does not produce significantly increased fear 
responses observed after administration produced by the other anaesthetics. 
AcbSh - Anticipation of reward/fear and motivation 
Ketamine produces very significantly increased neuronal activity of the brain 
region associated with the anticipation of reward or fear, when compared to 
saline.  
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However, both R1 and R5 produce significantly less neuronal activity of this 
region, when compared to ketamine, similar to that of saline. 
This reinforces the notion that R1 produces significantly reduced fear-related 
behaviour than ketamine does. 
VTA – Reward/fear expression, startle response 
While all anaesthetics significantly increase stimulation of this region associated 
with fear expression, R5 produced significantly reduced activity of this region 
when compared to ketamine. Lesions of the VTA produced suppressed fear 
expression during conditioned startle response experiments, suggesting the role of 
the VTA in regulating levels of aversive emotional arousal [106]. 
This may imply that R5 produces significantly reduced fear-expression 
behaviour than ketamine anaesthesia. 
DMH - Cardiovascular response to emotional fear 
Both ketamine and R5 produced significantly increased neuronal activity in the 
brain region associated with controlling cardiovascular responses to fear (DMH) 
when compared to saline, however R1 showed significantly reduced neuronal 
activity in this region, when  compared to ketamine. Studies show symptoms of 
stress response behaviour observed by stimulation of DMH included increase of 
respiratory rate, heart rate and arterial pressure [92].This may imply that R1 
produces a significant reduction in stimulation of the cardiovascular responses 
to fear than regular ketamine does.  R1 was again shown to influence this region 
the least compared to saline, as seen in the PVN; however increased neuronal 
activity of the DMH by ketamine and R5 correlated with inhibition of activity 
in the PVN. 
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5.1.6 Amnesia/memory retrieval and hallucination pathway 
CPu - Memory-retrieval, habit-formation and learned response 
Ketamine and R1 both produced significantly increased immunoreactivity in the 
region associated with habit and memory (CPu) when compared to saline.  
However, R5 did not produce significant changes compared to saline, implying 
that memory-retrieval regions, often associated with hallucinations, may not be 
activated in the way ketamine and R1 do. Stimulation studies show that the 
caudate putamen is required for the expression and consolidation of memory, 
while inhibition results in attenuated memory consolidation and retrieval [82], 
and has been implicated in hallucinations, mediating prefrontal behaviours and 
in the conceptual integration of memories [83]. This may imply that more 
significant amnesia and reduced hallucinations are produced during R5 
administration, than ketamine which often produces emergence reactions 
associated with hallucinatory behaviour. R5 also produced significantly reduced 
activity of this region when compared to ketamine. 
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5.2 Investigate the behavioural effects of ketamine-
analogues directly administered in pain and addiction 
pathways. 
By then focussing on nociception and addiction areas that showed significant 
changes, we were able to conduct behavioural studies during direct 
administration to the sites of interest, to further examine these effects. This 
included testing of analgesic effects and co-administering the drug with an ion-
channel blocker to investigate the mechanism of action for effective analgesia. 
 
5.2.1 AIC: Tail flick study 
c-Fos results of intravenous administration showed that all anaesthetic agents 
produced inhibition of neuronal activity in this region associated with 
perception of pain, with the novel ketamine analogues producing the most 
significant effect.  
Therefore, R5 was administered directly to this region to examine if this results 
in effective analgesia measured by behavioural responses.  
Direct injection: 
- Direct bilateral injection of R5 into the insular cortex resulted in modest 
attenuated pain response in rats (but significantly less than systemic 
administration). 
The observed result that direct injection into the AIC resulted in significantly 
less inhibited pain response than systemic administration implies that regions 
other than the AIC are responsible for the full analgesic effect produced by 
systemic administration.  
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5.2.2 ICV: Tail flick study 
In an attempt to further investigate the mechanism of action by which R5 produces 
analgesic effects, a second behavioural study administered R5 directly to the HPA-
axis by ICV injection, preceded by barium chloride administration. This aimed to 
test the hypothesis that barium blocks two-pore potassium (K2P) ion channels in 
neuronal membranes required for analgesic effects of anaesthetics. 
By directly administering into the ventricle, diffusion into the entire 
hypothalamic region can be attained without damage to any specific area [114].  
To investigate the hypothesis that analgesic effects of these drugs require 
functional two-pore potassium (K2P) ion channels in neuronal membranes, 
direct administration of R5 into the ventricle preceded by either barium chloride 
or saline was conducted. Barium has been shown to block (K2P) two-pore 
potassium ion channels in neuronal membranes, blocking anaesthetic agents 
from reaching the hydrophobic pockets of microtubules to initiate anaesthetic 
effects [115; 116].  
The results show that R5 is an effective analgesic when administered in this 
region, and that barium chloride produced a marked decrease in tail flick 
response time (6s to 3s), up to 8mins after administration of barium chloride and 
R5, when compared to saline and R5. After the 8min mark, barium chloride 
appears to be metabolised and begins to show more similar responses between 
groups. 
These results imply that barium chloride produced inhibition of the analgesic 
effect of R5 early on, before being metabolized after around 8 minutes, after 
which the analgesic effect was similar between groups. 
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The result of the administration of BaCl preceding anaesthetic administration 
described in the present study reinforced the hypothesis of barium K2P blockade, 
as the group receiving BaCl showed markedly decreased tail-flick response 
times when compared to the saline control group.  
Therefore, functioning K2P ion channels seem to be required for anaesthetic 
agents to produce effective analgesia. 
5.2.3 PVN: Exercise withdrawal study 
Finally, as the nociception system is also involved in addiction and withdrawal 
behaviours, the effect of R5 in reducing addictive-like, exercise-induced 
withdrawal symptoms was investigated. This was achieved by direct 
administration of R5 to the PVN after addictive-like, exercise-induced 
withdrawal, before behavioural effects were examined. 
The results of the exercise withdrawal study showed a strong trend (p=0.0592) 
of R5 producing reduced opioid-withdrawal behaviour symptoms, when 
compared to saline. 
This opioid-withdrawal behaviour included escape attempts, teeth chattering 
and wet-dog shakes, associated with increased stress and arousal. 
c-Fos studies of R5 intravenously show that the drug produces significantly 
inhibited immunoreactivity in the PVN, associated with reduced stress response. 
This reinforces the behavioural findings that R5 has inhibited stress responses 
associated with opioid withdrawal. 
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6. Conclusions and perspectives 
 
 
6.1 Conclusions 
The present project, utilizing rats as an animal model, focused on examining 
functional properties of the ester-analogue of ketamine, R5, whose potentially 
beneficial profile had been suggested by preliminary studies. First, brain 
activation patterns following R5 compared to ketamine (and another ester-
analogue control compound, R1) were assessed by employing 
immunohistochemical detection of an immediate-early gene product, c-Fos.  
- R5 produced a somewhat similar pattern of activity as ketamine, whereas more 
profound differences in c-Fos were detected after R1. It was particularly striking 
in areas related to pain and addiction, including the anterior insular cortex (AIC) 
and paraventricular nucleus (PVN).  
 
In response to these neurological markers, behavioural studies were shown to 
reinforce these findings, with R5 producing analgesic effects when administered 
directly to associated regions (AIC), and reduce stress-associated withdrawal 
behaviour when administered to the PVN.  
- AIC administration of R5 produced modest analgesia in the tail-flick test. 
- PVN R5 reduced naltrexone-precipitated exercise-induced withdrawal. 
- BaCl attenuated ICV R5-induced analgesia. 
In summary, R5 shows an analgesic effect similar to ketamine, most likely by 
targeting a similar subset of brain sites, which suggests that this particular ester-
analogue can be considered as a good candidate for conceptualizing future pain 
management strategies.  
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6.2 Perspectives 
Ketamine has long been shown to produce disturbing emergence reactions that 
have severely reduced patient acceptance, even though ketamine is one of the 
safest anaesthetic agents available. These reactions often include severely 
increased arousal and fear responses upon waking up, nausea and even 
hallucinations.  
The present study intended to refine the effects of ketamine anaesthesia by 
testing novel ketamine analogues in their comparative effects. 
c-Fos expression shows significant changes in activity of brain regions 
associated with these symptoms.  
Specifically, R1 produced increased analgesia, decreased fear response and 
arousal, however indicates an increase in some aspects of stress response, 
compared to ketamine. 
R5 also produced increased analgesia, and possibly amnesia, as memory 
retrieval regions were inhibited, perhaps contributing to reduced hallucinations. 
Decreased arousal, stress and fear -associated activity was also observed, 
however some measures of cardiovascular stress regions were shown to increase 
in activity (Figure 36). 
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Significant changes compared to ketamine: 
 
In response to these neurological markers, behavioural studies were shown to 
reinforce these findings, with R5 producing analgesic effects when administered 
directly to associated regions (AIC), and reduce stress-associated behaviour 
when administered to PVN.  
The present study therefore shows that novel ketamine-analogues produce 
similar effects to ketamine, however R5 in particular elicits significant changes 
in patterns of neuronal activity relating to pain pathways, and therefore may be 
an especially eligible candidate for further research to bring this drug to clinical 
use, as it appears to reduce signs of troubling side-effects often reported with 
ketamine anaesthesia. 
Future research could utilise rt-PCR techniques to better understand the 
comparative changes occurring at a gene-expression level contributing to 
reduced side-effects during anaesthesia. Findings such as the fact that R5 
produced significantly reduced neuronal activity of the caudate putamen, a 
region associated with memory-recall and hallucinations, would be interesting 
to follow up with behavioural studies perhaps in humans. By examining the 
Figure 36. Summary of function-related c-Fos results for each novel anaesthetic 
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difference in subjective experiences under anaesthesia, the hypothesis that R5 
may produce reduced hallucinations, one of the most troubling emergence 
reactions and a reason it is abused recreationally, can be investigated, leading to 
a safer clinical drug. Finally, to better address the common side-effect of nausea 
after ketamine anaesthesia, utilising an alternative method of slicing the brain 
before measuring immunoreactivity of the area postrema would increase the 
sample size and better allow observation of any significant effect in this area. 
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7. Supplementary Material 
 
Table 2. AIC c-Fos p-values 
 
Table 3. AP c-Fos p-values  
  p-value 
ketamine  r1 0.6512 
 r5 0.8527 
 saline 0.7875 
   
 
Table 4. NTS c-Fos p-values 
 
Table 5. BNST cFos p-values 
  p-value 
ketamine  r1 0.1433 
 r5 0.6947 
 saline 0.8748 
 
 
  
  p-value 
ketamine  r1 0.2939 
  r5 0.1834 
 saline 0.6115 
  p-value  
saline r1 0.0059 ** 
 r5 0.0085 ** 
 ketamine  0.6115  
  p-value 
Saline r1 0.5054 
 r5 0.5927 
 ketamine  0.7875 
  p-value 
saline r1 0.1329 
 r5 0.8268 
 ketamine  0.8748 
Table 6. BLA cFos p-values 
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Table 7. CeA cFos p-values 
  p-value  
ketamine  r1 0.6866  
 r5 0.3747  
 saline 0.0577 Strong trend 
 
 
 
 
 
 
 
Table 8. CPu cFos p-values 
 
Table 9. PVT cFos p-values 
 
Table 10. PVN cFos p-values 
 
Table 11. DMH cFos p-values 
 
  p-value   
saline r1 0.0177 *  
 r5 0.0045 **  
 ketamine  0.0577 Strong trend 
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Table 12. VMH cFos p-values 
 
Table 13. AcbC cFos p-values 
 
Table 14. AcbSh cFos p-values 
 
Table 15. VTA cFos p-values 
Table 16. PVN exercise withdrawal p-values  
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